SCG CELL
Location: Singapore
Employees: 51-200
Founded date: 2017
Mentions in press and media 18
| Date | Title | Description |
| 04.07.2024 | Breakthrough in Cancer Treatment: SCG Cell Therapy's Next-Generation HPV-Specific TCR T Cell Therapy | SCG Cell Therapy, a biotech company, has received FDA clearance for SCG142, a cutting-edge TCR T cell therapy for HPV-associated solid tumors. This innovative treatment shows promise in revolutionizing cancer care. SCG Cell Therapy's SCG142... |
| 01.07.2024 | SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors | SINGAPORE, July 1, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (F... |
| 30.06.2024 | SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors | SINGAPORE, June 30, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (... |
| 07.06.2024 | EASL Wrap-up Session Highlighted Late-Breaking Clinical Data of First-in-class HBV-specific TCR T Cell Therapy (SCG101) Showing Improved Overall Survival in HBV-related Hepatocellular Carcinoma | SINGAPORE, June 7, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced that clinical data from its firs... |
| 13.05.2024 | SCG Cell Therapy Presented New Preclinical Data in an Oral Presentation at ASGCT 2024 Annual Meeting Highlighting Superior Tumor Inhibition of its Immunoswitch Armored HPV-TCR T Cell Therapy (SCG142) ... | SINGAPORE, May 13, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced first preclinical data of its no... |
| 17.04.2024 | SCG CELL THERAPY AND A*STAR LAUNCH JOINT LABS WITH COLLABORATION NEARING S$30 MILLION TO ADVANCE iPSC TECHNOLOGY TOWARDS SCALABLE GMP MANUFACTURING OF CELLULAR IMMUNOTHERAPIES | Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of novel cellular immunotherapies. Launch of the joint labs builds on existing license, r... |
| 14.11.2023 | SCG Cell Therapy Announces Late-Breaking Clinical Data at AASLD Showing SCG101 Improved Tumor Reponses and Achieved Sustained Antiviral Activates in Patients with Advanced HBV-related Hepatocellular C... | SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced late-breaking clinical da... |
| 19.07.2023 | Significantly Reduce Manufacturing Cost and Increased Local Production: SCG Cell Therapy Opens State-of-the-art Cell Therapy Manufacturing Facility and R&D Centre in Singapore | SCG Cell Therapy celebrates the opening of its new Cell Therapy Manufacturing Facility and R&D Centre, launching a new first-of-its-kind automatic cell therapy manufacturing system in Singapore, pioneering Singapore's Manufacturing 2030... |
| 12.07.2023 | Best Presentation Award at EASL Congress 2023: First-in-class Bispecific Antibodies Anti-HBs×CD3 and Anti-HBs×CD28 Showed Strong Preclinical Efficacy in HBV Cure | SINGAPORE, July 12, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, together with researchers from the Univer... |
| 05.06.2023 | ISCT 2023: Late-breaking SCG101 Data Show 100% HBsAg+ Hepatocyte Eradication and 74.5% HCC Tumour Reduction With Single Dose HBsAg-specific TCR-T Cell Therapy | SINGAPORE, June 5, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, presented late-breaking data from its firs... |
Show more